RITA GIGLIO: Open Payments
NPI 1811504038 · CLAREMORE, OK. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$740 in 54 payments from 11 companies in 2025. Trend: 2023 $59 · 2024 $538 · 2025 $740
Food & beverage: $656Education: $84
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 25 | $219 |
| ABBVIE INC. | 14 | $176 |
| Teva Pharmaceuticals USA, Inc. | 2 | $102 |
| Lundbeck LLC | 3 | $54 |
| Almatica Pharma LLC | 2 | $46 |
| Alkermes, Inc. | 2 | $43 |
| Vanda Pharmaceuticals Inc. | 2 | $37 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
| Axsome Therapeutics, Inc. | 1 | $16 |
| Supernus Pharmaceuticals, Inc. | 1 | $15 |
Products named: INGREZZA, VRAYLAR, REXULTI, LOREEV XR, ARISTADA, FANAPT, AUSTEDO XR, ABILIFY MAINTENA.
Industry payments across OK — which companies pay providers there.
